StockData
Travere Therapeutics, Inc. logo

Travere Therapeutics, Inc. (TVTX) stock

TVTXNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2027, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 2, 2026Score 6/30751% above fair value
$51.10+1.40 (+2.82%)

Close on Nov 17, 2026Market cap $4.82BP/E –Yield –

Travere Therapeutics enterprise value

Enterprise value is market cap plus debt, minus cash: the value of the whole business to all its investors.

Travere Therapeutics's enterprise value was $4.61B on Nov 11, 2026, against $2.92B a year earlier. Over the last 5 years it ranged from $109.97M to $5.95B, with a median of $1.14B.

Enterprise Value at the end of each year

PeriodPeriod endValueChange
2026Nov 11, 2026$4.61B+45.4%
2025Dec 31, 2025$3.17B+187.6%
2024Dec 31, 2024$1.10B+246.1%
2023Dec 29, 2023$318.38M-64.7%
2022Dec 30, 2022$901.00M-37.5%
2021Dec 31, 2021$1.44B+45.4%
2020Dec 31, 2020$991.37M+215.8%
2019Dec 31, 2019$313.91M-48.0%
2018Dec 31, 2018$603.35M-17.2%
2017Dec 29, 2017$728.65M+5.6%
2016Dec 30, 2016$689.84M+24.5%
2015Dec 31, 2015$554.00M+64.7%
2014Dec 31, 2014$336.46M+192.0%
2013Dec 31, 2013$115.22M+32493.6%
2012Dec 31, 2012$353.52K–

More Travere Therapeutics figures

See a number that looks wrong?